OBJECTIVE: The phenotype of the antioxidant and pro-angiogenic protein haptoglobin (Hp) predicts cardiovascular disease risk and treatment response to antioxidant vitamins in individuals with diabetes. Our objective was to determine whether Hp phenotype influences pre-eclampsia risk, or the efficacy of vitamins C and E in preventing pre-eclampsia, in women with type-1 diabetes. DESIGN: This is a secondary analysis of a randomised controlled trial in which women with diabetes received daily vitamins C and E, or placebo, from 8 to 22 weeks of gestation until delivery. SETTING: Twenty-five antenatal metabolic clinics across the UK (in north-west England, Scotland, and Northern Ireland). POPULATION: Pregnant women with type-1 diabetes. METHODS: Hp phenotype was determined in white women who completed the study and had plasma samples available (n = 685). MAIN OUTCOME MEASURE: Pre-eclampsia. RESULTS: Compared with Hp 2-1, Hp 1-1 (OR 0.59, 95% CI 0.30-1.16) and Hp 2-2 (OR 0.93, 95% CI 0.60-1.45) were not associated with significantly decreased pre-eclampsia risk after adjusting for treatment group and HbA1c at randomisation. Our study was not powered to detect an interaction between Hp phenotype and treatment response; however, our preliminary analysis suggests that vitamins C and E did not prevent pre-eclampsia in women of any Hp phenotype (Hp 1-1, OR 0.77, 95% CI 0.22-2.71; Hp 2-1, OR 0.81, 95% CI 0.46-1.43; Hp 2-2, 0.67, 95% CI 0.34-1.33), after adjusting for HbA1c at randomisation. CONCLUSIONS: The Hp phenotype did not significantly affect pre-eclampsia risk in women with type-1 diabetes.
OBJECTIVE: The phenotype of the antioxidant and pro-angiogenic protein haptoglobin (Hp) predicts cardiovascular disease risk and treatment response to antioxidant vitamins in individuals with diabetes. Our objective was to determine whether Hp phenotype influences pre-eclampsia risk, or the efficacy of vitamins C and E in preventing pre-eclampsia, in women with type-1 diabetes. DESIGN: This is a secondary analysis of a randomised controlled trial in which women with diabetes received daily vitamins C and E, or placebo, from 8 to 22 weeks of gestation until delivery. SETTING: Twenty-five antenatal metabolic clinics across the UK (in north-west England, Scotland, and Northern Ireland). POPULATION: Pregnant women with type-1 diabetes. METHODS: Hp phenotype was determined in white women who completed the study and had plasma samples available (n = 685). MAIN OUTCOME MEASURE: Pre-eclampsia. RESULTS: Compared with Hp 2-1, Hp 1-1 (OR 0.59, 95% CI 0.30-1.16) and Hp 2-2 (OR 0.93, 95% CI 0.60-1.45) were not associated with significantly decreased pre-eclampsia risk after adjusting for treatment group and HbA1c at randomisation. Our study was not powered to detect an interaction between Hp phenotype and treatment response; however, our preliminary analysis suggests that vitamins C and E did not prevent pre-eclampsia in women of any Hp phenotype (Hp 1-1, OR 0.77, 95% CI 0.22-2.71; Hp 2-1, OR 0.81, 95% CI 0.46-1.43; Hp 2-2, 0.67, 95% CI 0.34-1.33), after adjusting for HbA1c at randomisation. CONCLUSIONS: The Hp phenotype did not significantly affect pre-eclampsia risk in women with type-1 diabetes.
Authors: J Villar; M Purwar; M Merialdi; N Zavaleta; N Thi Nhu Ngoc; J Anthony; A De Greeff; L Poston; A Shennan Journal: BJOG Date: 2009-05 Impact factor: 6.531
Authors: Andrew P Levy; Irit Hochberg; Kathleen Jablonski; Helaine E Resnick; Elisa T Lee; Lyle Best; Barbara V Howard Journal: J Am Coll Cardiol Date: 2002-12-04 Impact factor: 24.094
Authors: Tracey L Weissgerber; James M Roberts; Arun Jeyabalan; Robert W Powers; Minjae Lee; Saul A Datwyler; Robin E Gandley Journal: Am J Obstet Gynecol Date: 2012-01-13 Impact factor: 8.661
Authors: Dorte M Jensen; Peter Damm; Lars Moelsted-Pedersen; Per Ovesen; Jes G Westergaard; Margrethe Moeller; Henning Beck-Nielsen Journal: Diabetes Care Date: 2004-12 Impact factor: 19.112
Authors: Douglas Altman; Guillermo Carroli; Lelia Duley; Barbara Farrell; Jack Moodley; James Neilson; David Smith Journal: Lancet Date: 2002-06-01 Impact factor: 79.321
Authors: Lucy C Chappell; Paul T Seed; Annette Briley; Frank J Kelly; Beverley J Hunt; D Stephen Charnock-Jones; Anthony I Mallet; Lucilla Poston Journal: Am J Obstet Gynecol Date: 2002-07 Impact factor: 8.661
Authors: Olukunmi O Balogun; Katharina da Silva Lopes; Erika Ota; Yo Takemoto; Alice Rumbold; Mizuki Takegata; Rintaro Mori Journal: Cochrane Database Syst Rev Date: 2016-05-06
Authors: Tracey L Weissgerber; Paula L McGee; Leslie Myatt; John C Hauth; Michael W Varner; Ronald J Wapner; John M Thorp; Brian M Mercer; Alan M Peaceman; Susan M Ramin; Philip Samuels; Anthony C Sciscione; Margaret Harper; George Saade; Yoram Sorokin Journal: J Matern Fetal Neonatal Med Date: 2014-01-13
Authors: Reyna Sámano; Hugo Martínez-Rojano; Rosa M Hernández; Cristina Ramírez; María E Flores Quijano; José M Espíndola-Polis; Daniela Veruete Journal: Nutrients Date: 2017-01-01 Impact factor: 5.717
Authors: Tracey L Weissgerber; Robin E Gandley; Paula L McGee; Catherine Y Spong; Leslie Myatt; Kenneth J Leveno; John M Thorp; Brian M Mercer; Alan M Peaceman; Susan M Ramin; Marshall W Carpenter; Philip Samuels; Anthony Sciscione; Margaret Harper; Jorge E Tolosa; George Saade; Yoram Sorokin Journal: PLoS One Date: 2013-04-03 Impact factor: 3.240